File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B

TitleEfficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
Authors
KeywordsActive immunization
Antibody against hepatitis B surface antigen
Immunity
Recurrence
Issue Date2007
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
Citation
American Journal Of Transplantation, 2007, v. 7 n. 2, p. 434-439 How to Cite?
AbstractLamivudine monoprophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants and second generation recombinant HBV vaccine is not effective. We studied the efficacy of two courses each of three double-doses (20 ug) of third-generation recombinant pre-S containing vaccine (Sci-B-Vac™) in 20 patients on lamivudine prophylaxis at a median of 637 days (range, 390-2666 days) after transplantation. At enrollment, all patients were seronegative for HBsAg, anti-HBs and HBVDNA (by qPCR). Lamivudine (100 mg/day) was continued throughout the study. Five patients (25%) responded to the first course and five additional patients responded after the second course (overall response rate 50%). The response rate was 88% in patients younger than 50 years old and 25% in older patients (p = 0.02). The median peak anti-HBs titer was 153 mIU/mL with six responders having a titer >100 mIU/mL and seven sustained >6 months. Among seven previous nonresponders to second generation recombinant vaccine, three (44%) responded. At the end of the study, all patients remained seronegative for HBsAg. In conclusion, Sci-B-Vac™ is effective in about 50% of patients receiving lamividine prophylaxis and may prevent recurrence due to escape mutants. © 2006 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/54321
ISSN
2015 Impact Factor: 5.669
2015 SCImago Journal Rankings: 2.792
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLo, CMen_HK
dc.contributor.authorLau, GKen_HK
dc.contributor.authorChan, SCen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorWong, Jen_HK
dc.date.accessioned2009-04-03T07:43:12Z-
dc.date.available2009-04-03T07:43:12Z-
dc.date.issued2007en_HK
dc.identifier.citationAmerican Journal Of Transplantation, 2007, v. 7 n. 2, p. 434-439en_HK
dc.identifier.issn1600-6135en_HK
dc.identifier.urihttp://hdl.handle.net/10722/54321-
dc.description.abstractLamivudine monoprophylaxis against hepatitis B virus (HBV) reinfection after liver transplantation is associated with recurrence due to escape mutants and second generation recombinant HBV vaccine is not effective. We studied the efficacy of two courses each of three double-doses (20 ug) of third-generation recombinant pre-S containing vaccine (Sci-B-Vac™) in 20 patients on lamivudine prophylaxis at a median of 637 days (range, 390-2666 days) after transplantation. At enrollment, all patients were seronegative for HBsAg, anti-HBs and HBVDNA (by qPCR). Lamivudine (100 mg/day) was continued throughout the study. Five patients (25%) responded to the first course and five additional patients responded after the second course (overall response rate 50%). The response rate was 88% in patients younger than 50 years old and 25% in older patients (p = 0.02). The median peak anti-HBs titer was 153 mIU/mL with six responders having a titer >100 mIU/mL and seven sustained >6 months. Among seven previous nonresponders to second generation recombinant vaccine, three (44%) responded. At the end of the study, all patients remained seronegative for HBsAg. In conclusion, Sci-B-Vac™ is effective in about 50% of patients receiving lamividine prophylaxis and may prevent recurrence due to escape mutants. © 2006 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJTen_HK
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsThe definitive version is available at www.blackwell-synergy.comen_HK
dc.subjectActive immunizationen_HK
dc.subjectAntibody against hepatitis B surface antigenen_HK
dc.subjectImmunityen_HK
dc.subjectRecurrenceen_HK
dc.subject.meshAntibody Formationen_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshHepatitis B Vaccines - therapeutic useen_HK
dc.subject.meshHepatitis B, Chronic - etiology - immunology - prevention & controlen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.titleEfficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1600-6135&volume=7&issue=2&spage=434&epage=439&date=2007&atitle=Efficacy+of+a+pre-S+containing+vaccine+in+patients+receiving+lamivudine+prophylaxis+after+liver+transplantation+for+chronic+hepatitis+Ben_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityChan, SC=rp01568en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturepostprinten_HK
dc.identifier.doi10.1111/j.1600-6143.2006.01636.xen_HK
dc.identifier.pmid17283489-
dc.identifier.scopuseid_2-s2.0-33846205528en_HK
dc.identifier.hkuros126108-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846205528&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume7en_HK
dc.identifier.issue2en_HK
dc.identifier.spage434en_HK
dc.identifier.epage439en_HK
dc.identifier.isiWOS:000243440100021-
dc.publisher.placeDenmarken_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridLau, GK=7102301257en_HK
dc.identifier.scopusauthoridChan, SC=7404255575en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK
dc.identifier.citeulike1047405-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats